About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
European Urology Supplements
›
Top Articles
European Urology Supplements
0.9
(top 33%)
Impact Factor
0.9
(top 33%)
extended IF
30
(top 13%)
H-Index
709
authors
1.2K
papers
6.6K
citations
1.8K
citing journals
6K
citing authors
Most Cited Articles of European Urology Supplements
Title
Year
Citations
Outcome of GreenLight HPS 120-W Laser Therapy in Specific Patient Populations: Those in Retention, on Anticoagulants, and with Large Prostates (≥ 80ml)
2008
76
Benign Prostatic Hyperplasia and Its Aetiologies
2009
75
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer
2008
69
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events
2008
64
Nocturia: consequences for sleep and daytime activities andassociated risks
2005
63
Techniques and Training with GreenLight HPS 120-W Laser Therapy of the Prostate: Position Paper
2008
62
The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study
2005
60
Potential Benefits of Muscarinic M3 Receptor Selectivity
2002
55
The physiology of sleep and the impact of ageing
2005
54
Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis
2010
49
Testosterone Associations with Erectile Dysfunction, Diabetes, and the Metabolic Syndrome
2007
46
Staging and Staging Errors in Bladder Cancer
2010
45
Ureteropelvic Junction Obstruction
2012
44
Transurethral Resection of the Prostate
2009
44
Ileal Conduit as the Standard for Urinary Diversion After Radical Cystectomy for Bladder Cancer
2010
43
The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS®)
2005
41
Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO)
2005
40
CLINICAL PROOF OF CONCEPT STUDY (BLOSSOM) SHOWS NOVEL β3 ADRENOCEPTOR AGONIST YM178 IS EFFECTIVE AND WELL TOLERATED IN THE TREATMENT OF SYMPTOMS OF OVERACTIVE BLADDER
2008
39
Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer
2009
38
Obstructive Bladder Dysfunction: Morphological, Biochemical and Molecular Changes
2002
37
Should We Investigate Prostatic Inflammation for the Management of Benign Prostatic Hyperplasia?
2009
35
Improved Classification of Urinary Tract Infection: Future Considerations
2016
34
Bladder Cancer: A Major Public Health Issue
2008
32
Cytology and Urinary Markers for the Diagnosis of Bladder Cancer
2009
31
Early Complications and Morbidity of Radical Cystectomy
2010
30
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.